Gamma-secretase inhibitors (GSIs) block the activation of the oncogenic protein Notch homolog-1 (NOTCH1) in T cell acute lymphoblastic leukemia (T-ALL). However, limited antileukemic cytotoxicity and severe gastrointestinal toxicity have restricted the clinical application of these targeted drugs. Here we show that combination therapy with GSIs plus glucocorticoids can improve the antileukemic effects of GSIs and reduce their gut toxicity in vivo. Inhibition of NOTCH1 signaling in glucocorticoid-resistant T-ALL restored glucocorticoid receptor autoupregulation and induced apoptotic cell death through induction of the gene encoding BCL-2-like apoptosis initiator-11 (BCL2L11). GSI treatment resulted in cell cycle arrest and accumulation of goblet cells in the gut mediated by upregulation of the gene encoding the transcription factor Krü ppel-like factor-4 (Klf4), a negative regulator of the cell cycle required for goblet cell differentiation. In contrast, glucocorticoid treatment induced transcriptional upregulation of cyclin D2 (Ccnd2) and protected mice from developing the intestinal goblet cell metaplasia typically induced by inhibition of NOTCH signaling with GSIs. These results support a role for glucocorticoids plus GSIs in the treatment of glucocorticoid-resistant T-ALL.
Gamma-secretase inhibitors (GSIs) block the activation of the oncogenic protein Notch homolog-1 (NOTCH1) in T cell acute lymphoblastic leukemia (T-ALL). However, limited antileukemic cytotoxicity and severe gastrointestinal toxicity have restricted the clinical application of these targeted drugs. Here we show that combination therapy with GSIs plus glucocorticoids can improve the antileukemic effects of GSIs and reduce their gut toxicity in vivo. Inhibition of NOTCH1 signaling in glucocorticoid-resistant T-ALL restored glucocorticoid receptor autoupregulation and induced apoptotic cell death through induction of the gene encoding BCL-2-like apoptosis initiator-11 (BCL2L11). GSI treatment resulted in cell cycle arrest and accumulation of goblet cells in the gut mediated by upregulation of the gene encoding the transcription factor Krü ppel-like factor-4 (Klf4), a negative regulator of the cell cycle required for goblet cell differentiation. In contrast, glucocorticoid treatment induced transcriptional upregulation of cyclin D2 (Ccnd2) and protected mice from developing the intestinal goblet cell metaplasia typically induced by inhibition of NOTCH signaling with GSIs. These results support a role for glucocorticoids plus GSIs in the treatment of glucocorticoid-resistant T-ALL.
GSIs, which block the presenilin-g-secretase complex, inhibit the production of amyloidogenic b-amyloid peptides involved in the pathogenesis of Alzheimer's disease and the activation of NOTCH receptors 1, 2 . The recent identification of activating mutations in the NOTCH1 receptor gene in over 50% of cases of T-ALL 3 prompted the initiation of a clinical trial to test the effectiveness of blocking NOTCH1 signaling with a small molecule GSI in this disease 4, 5 . However, the clinical development of GSI-based therapies has been hampered by the limited ability of these drugs to induce apoptosis in human T-ALL 6, 7 and by the development of severe gastrointestinal toxicity due to inhibition of NOTCH signaling in the gut 5, [8] [9] [10] [11] .
Here we show that inhibition of NOTCH1 signaling with a GSI can reverse glucocorticoid resistance in T-ALL and that concurrent dexamethasone treatment protects mice from severe secretory metaplasia [8] [9] [10] [11] induced by inhibition of NOTCH signaling in the gut.
RESULTS
GSI treatment reverses glucocorticoid resistance in T-ALL NOTCH1 signaling has a key role in the specification of cell fate and maintenance of cell tropism during T cell development 12, 13 . Aberrant NOTCH1 signaling can protect developing thymocytes against glucocorticoid-induced cell death 14 and is a crucial oncogenic event in the pathogenesis of T-ALL [15] [16] [17] . To test whether aberrant NOTCH1 signaling contributes to glucocorticoid resistance in T-ALL, we analyzed the responses of human T-ALL cells to increased doses of dexamethasone in the presence of Compound E, a highly active GSI 18 . CUTLL1 cells, a well characterized T cell lymphoblastic cell line with activated NOTCH1 (ref. 6) , are highly resistant to glucocorticoids, showing only a minimal loss of cell viability when treated with dexamethasone concentrations as high as 1 Â 10 À5 M (Fig. 1a) . Treatment of CUTLL1 cells with 100 nM Compound E for 72 h effectively blocks NOTCH1 signaling and induces a modest cytostatic response characterized by G1 cell cycle arrest ( Supplementary Fig. 1 online) 6, 19, 20 . By contrast, treatment of CUTLL1 cells with dexamethasone in the presence of Compound E (100 nM) effectively impaired cell viability, with a 50% inhibitory concentration (IC 50 ) value of 7.7 Â 10 À8 M for dexamethasone in the presence of Compound E at 72 h (Fig. 1a) . Similarly, dose-response analysis of CUTLL1 cells treated with dexamethasone (100 nM) and a range of Compound E concentrations showed a synergistic dose-dependent response to this GSI in combination with dexamethasone ( Supplementary Fig. 2 online). Subsequent analysis of KOPTK1 and TALL1 cells, two additional glucocorticoid-resistant T-ALL cell lines that respond with G1 cell cycle arrest upon Compound E treatment 3 ( Supplementary  Fig. 1 ), showed significant decreases in cell viability when treated with dexamethasone plus Compound E (P o 0.001), indicative of a synergistic interaction between these agents ( Fig. 1a) . Analysis of glucocorticoid-sensitive cell lines (DND41 and P12-ICHIKAWA cells) or B cell-derived tumors devoid of NOTCH1 activation (Raji and Ramos cells) showed no evidence of synergistic interaction between Compound E and dexamethasone ( Fig. 1b) . Similarly, analysis of eight T-ALL primary samples from human subjects at relapse showed synergistic interaction between Compound E and dexamethasone in two out of three glucocorticoid-resistant tumors but not in leukemias retaining glucocorticoid sensitivity ( Fig. 1c and Supplementary Fig. 3 online) .
The synergistic effects of Compound E plus dexamethasone observed in CUTLL1 cells were reversed by treatment with RU486, a glucocorticoid receptor antagonist ( Fig. 1d) . Similarly, expression of an intracellular activated NOTCH1 (ICN1), which does not require g-secretase cleavage, bypassed the inhibitory effects of GSIs on NOTCH1 signaling and protected CUTLL1 cells from the effects of dexamethasone plus Compound E treatment ( Fig. 1e and Supplementary Fig. 4 online) . These data, together with the lack of synergism between Compound E and other antileukemic drugs (Supplementary Results, Supplementary Discussion and Supplementary Fig. 5 online), demonstrate a specific interaction between GSIs and glucocorticoids in T-ALL.
Next, we asked whether the synergistic effects of Compound E plus dexamethasone reflect enhanced apoptotic responses to glucocorticoid therapy. Annexin V-propidium iodide (PI) staining indicated increased apoptosis in CUTLL1, KOPTK1 and TALL1 cells treated with Compound E and dexamethasone for 48-72 h (Fig. 1f) . Additionally, western blot analysis of CUTLL1 cells treated with Compound E plus dexamethasone showed a marked increase in poly-(ADP-ribose) polymerase (PARP) cleavage, indicative of activation of effector caspases and apoptosis ( Fig. 1g ). Furthermore, Z-VAD, a pancaspase inhibitor, reversed the induction of PARP cleavage and apoptosis (detected by annexin V-PI staining) triggered by Compound E plus dexamethasone in this cell line ( Fig. 1g,h ).
NOTCH1 inhibition restores NR3C1 autoregulation
Both NOTCH1 and the glucocorticoid receptor function as ligandactivated transcription factors, suggesting that crosstalk between NOTCH1 signaling and glucocorticoid therapy may enhance the transcriptional response to dexamethasone in glucocorticoid-resistant T-ALL. To analyze the effects of glucocorticoid treatment in the transcriptional regulatory network controlled by NOTCH1 in T-ALL 19 and to explore the mechanisms mediating the reversal of glucocorticoid resistance upon NOTCH inhibition, we performed gene expression profiling with oligonucleotide microarrays in CUTLL1 cells treated with vehicle (DMSO), dexamethasone (1 mM), Compound E (100 nM) or both dexamethasone and Compound E for 24 h. This analysis showed a more efficient glucocorticoid response in cells treated with Compound E plus dexamethasone, with synergistic upregulation of glucocorticoid-regulated genes such as TSC22D3 (also known as GILZ), CD53, SOCS1 and BTG2 ( Fig. 2a and Supplementary Fig. 6 online) . Notably, the glucocorticoid receptor gene (NR3C1) ranked among the top genes synergistically upregulated by dexamethasone plus GSI treatment in our microarray analysis ( Fig. 2a) . Numerous studies on the mechanisms of glucocorticoid resistance have established that an effective upregulation of the NR3C1 gene in response to glucocorticoids is required for the activation of apoptosis in human leukemias [21] [22] [23] [24] [25] [26] . Quantitative RT-PCR and western blot analysis showed a moderate increase in glucocorticoid receptor expression in CUTLL1 cells and primary T-ALL lymphoblasts treated with GSI and dexamethasone ( Fig. 2b and Supplementary Fig. 3 ). In contrast, dexamethasone plus Compound E treatment resulted in a significantly higher (fivefold) upregulation of glucocorticoid receptor transcript and protein levels ( Fig. 2b) . These results suggest that inhibition of NOTCH1 signaling enhances glucocorticoid receptor autoupregulation and glucocorticoid sensitivity in otherwise glucocorticoid-resistant T-ALL cells (Supplementary Results and Supplementary Discussion). Consistent with this hypothesis, and in agreement with previous reports in T-ALL [27] [28] [29] , retroviral expression of the NR3C1 gene restored glucocorticoid sensitivity and enhanced the apoptotic response of CUTLL1 cells to dexamethasone ( Fig. 2c) .
Conversely, short hairpin RNA (shRNA) knockdown of the glucocorticoid receptor resulted in complete abrogation of the apoptosis induced by dexamethasone plus Compound E ( Fig. 2d ).
Glucocorticoid receptor autoupregulation has been linked to the function of NR3C1 promoter 1A (hematopoietic) and NR3C1 promoters 1B and 1C (ubiquitous) 25, [30] [31] [32] . Chromatin immunoprecipitation (ChIP)-on-chip analysis of Hairy and Enhancer of Split homolog-1 (HES1), a transcriptional repressor directly controlled by NOTCH1, identified HES1 binding in glucocorticoid receptor promoters 1B and 1C in T-ALL cells ( Supplementary Fig. 7 online). Subsequent quantitative ChIP assays confirmed HES1 binding to glucocorticoid receptor promoters 1B and 1C and also showed HES1 binding to regulatory sequences in promoter 1A, which was not represented on the ChIP-on-chip promoter microarray ( Fig. 2e) . Upregulation of the hematopoietic NR3C1 A1 promoter is mediated by a 35-base pair regulatory sequence (FP11-FP12) which is activated by a NR3C1-myeloblastosis oncoprotein (MYB) heterodimer complex upon glucocorticoid treatment 31 . Luciferase reporter assays showed that dexamethasone treatment and MYB expression activated a NR3C1 A1 FP11-FP12 reporter construct ( Fig. 2f ). Of note, HES1 expression antagonized the activation of the NR3C1 A1 promoter by dexamethasone, MYB and the combination of glucocorticoid treatment and MYB expression ( Fig. 2f ). Consistent with these results, shRNA knockdown of HES1 in CUTLL1 cells resulted in increased glucocorticoid receptor transcript and protein levels ( Fig. 2g ) and effective reversal of glucocorticoid resistance ( Fig. 2h ).
BCL2L11 upregulation reverses glucocorticoid resistance
Analysis of the expression of proapototic and antiapoptotic regulators of the mitochondrial cell-death pathway showed that BCL2L11, encoding a BH3-only protein (BIM) required for glucocorticoidinduced apoptosis [33] [34] [35] , was slightly upregulated by dexamethasone but markedly and synergistically upregulated in CUTLL1 cells treated with dexamethasone plus Compound E ( Fig. 3a) . Similarly, analysis of the gene encoding BCL2-modifying factor (BMF), a BH3-only protein involved in anoikis and cytoskeleton stress-induced apoptosis 36 , showed synergistic transcriptional upregulation in cells treated with Compound E plus dexamethasone ( Fig. 3b) . Similar results were obtained in KOPTK1 and TALL1 cells ( Supplementary Fig. 8 online) . Western blot analysis showed a marked (fivefold) upregulation of the proapoptotic factors BIML, encoded by the BCL2L11 isoform 6, and BIMS, encoded by the BCL2L11 isoform 9, in CUTLL1 cells treated with Compound E plus dexamethasone (Fig. 3c) . In contrast, transcriptional upregulation of BMF caused less consistent increases in BMF protein ( Fig. 3c ). Consistent with these results, shRNA knockdown of BCL2L11 effectively blocked the apoptosis induction by Compound E plus dexamethasone treatment in CUTLL1 cells ( Fig. 3d,e ), but downregulation of BMF by shRNA knockdown did not protect these cells from the apoptosis induced by such treatment (Fig. 3f,g) . Together, these results demonstrate that BCL2L11 upregulation mediates the reversal of glucocorticoid resistance in T-ALL cells treated with dexamethasone plus Compound E (Fig. 3h ).
Antileukemic effects of GSI and glucocorticoids in vivo
To test whether the synergistic effects of concurrent GSI and glucocorticoid treatment in vitro enhance the therapeutic efficacy of these agents in vivo, we analyzed the effects of dexamethasone and NOTCH inhibition in a xenograft model of glucocorticoidresistant T-ALL. In these experiments we used DBZ in vitro (Supplementary Fig. 9 online) and with well established activity in vivo 8 . CUTLL1 cells infected with lentiviruses expressing the gene encoding luciferase were injected subcutaneously in the flanks of immunodeficient (nonobese diabetic-severe combined immunodeficient (NOD-SCID)) mice. After 1 week, mice harboring homogeneous subcutaneous tumors were treated with vehicle only (DMSO), DBZ, dexamethasone or DBZ plus dexamethasone and monitored for 4 d with a bioimaging system to quantify luciferase activity. In this experiment, mice treated with dexamethasone showed progressive tumor growth similar to that observed in vehicle-treated controls, whereas mice treated with DBZ showed a moderate delay in tumor growth ( Fig. 4a,b ) consistent with the cytostatic effect of NOTCH1 inhibition by GSIs observed in CUTLL1 cells in vitro ( Supplementary  Fig. 1 ) 6 . By contrast, mice treated with DBZ plus dexamethasone had marked antitumor responses with a significant reduction in tumor burden after 4 d of treatment ( Fig. 4a,b ; P o 0.01). Notably, tumor xenografts of CUTLL1 cells expressing the activated intracellular form of NOTCH1 (CUTLL1-ICN1 cells; Supplementary  Fig. 4 ) were unresponsive to the combination of DBZ plus dexamethasone ( Fig. 4c) , indicating that reversal of glucocorticoid resistance in vivo by DBZ treatment is mediated by inhibition of NOTCH1 signaling in the leukemic cells.
To test the importance of these results in a xenograft model that may be a more faithful representation of the natural history of humans with T-ALL, we intravenously injected CUTLL1 cells expressing the luciferase marker into irradiated NOD-SCID mice. After 3 weeks, groups of mice with homogeneous tumor burdens were treated with vehicle only, dexamethasone, DBZ or DBZ plus dexamethasone for 2 weeks. Disease progression was readily apparent in control and dexamethasone-treated mice, resulting in tumor-related mortality starting 3 weeks after the initiation of the treatment (Fig. 4d) . Mice in the GSI-only treatment group developed weight loss and accelerated mortality at week 3 ( Fig. 4d and data not shown) despite having low levels of leukemia infiltration compared with DMSO and dexamethasone-treated mice (data not shown). Finally, all mice treated with DBZ plus dexamethasone were disease free, as determined by in vivo bioimaging 3 weeks after the initiation of the treatment (data not shown). However, two of these mice were euthanized on day 23 because of excessive (420%) weight loss ( Fig. 4d and data not shown). Analysis at the end of the observation period (10 weeks) showed significantly improved survival among mice treated with dexamethasone plus DBZ (P o 0.05 versus controls; Fig. 4d ).
Dexamethasone abrogates GSI-induced toxicity in the gut
The poor outcome observed in DBZ-treated mice, which harbored low levels of leukemia infiltration, suggested that GSI-induced toxicity might have contributed to their accelerated mortality. Moreover, the improved survival observed in mice treated with DBZ plus dexamethasone suggested that glucocorticoid therapy could ameliorate some of the toxic effects associated with GSI treatment. To test this hypothesis, we analyzed the effects of dexamethasone, DBZ or dexamethasone plus DBZ in C57/BL6 mice compared to vehicle-only treatment controls (Supplementary Results, Supplementary Discussion and Supplementary Fig. 10 online) . Histological analysis of multiple organs revealed marked changes induced by DBZ treatment in the intestine, thymus and the spleen ( Fig. 4e and Supplementary Fig. 11 online) . Thus, DBZ-treated mice showed severe intestinal secretory metaplasia characterized by a marked increase in the number of goblet cells and arrested cell proliferation (determined by Ki67 immunostaining) in the crypts of the small intestine 8-11 ( Fig. 4e and Supplementary Fig. 11 ).
Dexamethasone treatment induced mild changes in the architecture of the gut that were most apparent after 10 d of treatment, with moderate elongation of the intestinal crypts and accumulation of Paneth cells at the bottom of the crypt (Fig. 4e, Fig. 6d , Supplementary Results, Supplementary Discussion and Supplementary Fig. 11 online) . Of note, mice treated with DBZ plus dexamethasone showed normal goblet cell numbers with preservation of the architecture and proliferation of the intestinal epithelium ( Fig. 4e and Supplementary Fig. 11 ). Pharmacokinetic analysis ruled out increased DBZ clearance in mice treated with dexamethasone plus DBZ (Supplementary Results, Supplementary Discussion and Supplementary Fig. 12 online) as a mechanism of decreased GSI-induced gut toxicity. Moreover, histological analysis of the thymus and spleen showed increased lymphoid atrophy in mice treated with dexamethasone plus DBZ compared with mice treated with dexamethasone or DBZ alone ( Fig. 4e , Supplementary Results, Supplementary Discussion and Supplementary Figs. 13 and 14 online) .
To analyze whether dexamethasone treatment could also ameliorate the effects of NOTCH inactivation via deletion of the gene coding for recombination signal binding protein for immunoglobulin k J region (Rbpj, also known as Csl), which is the DNA binding protein component of the Notch transcriptional complex 9 , we crossed Rbpj flox/flox conditional knockout mice to the Cre-Tam mouse line, which expresses a tamoxifen-inducible Cre from the ubiquitous Rosa26 locus 37 and treated the resulting Rbpj flox/flox Cre-Tam mice with tamoxifen or tamoxifen plus dexamethasone. In this experiment, mice treated with tamoxifen showed increased numbers of goblet cells induced by ablation of Notch signaling in the gut. In contrast, mice treated with tamoxifen plus dexamethasone were protected from developing goblet cell metaplasia upon genetic inactivation of Notch signaling in the gut (Fig. 4f ).
Klf4 upregulation in GSI-induced gut toxicity
The Klf4 tumor suppressor gene encodes a Krüppel-like zinc finger transcription factor required for intestinal goblet cell differentiation 38, 39 . Immunohistochemical analysis of Klf4 in the intestines of mice treated with DMSO, dexamethasone, DBZ or DBZ plus dexamethasone showed nuclear staining in goblet cells in the villi and in scattered cells in the crypts of control and dexamethasone-treated mice (Fig. 5a) . In contrast, mice treated with DBZ showed a marked increase in the number of Klf4-positive cells in the crypts and in the villi, which was abrogated by glucocorticoid treatment in mice treated with DBZ plus dexamethasone (Fig. 5a,b and Supplementary Fig. 15 online). Similarly, quantitative RT-PCR analysis showed increased levels of Klf4 expression in the gut of mice treated with DBZ but not in mice treated with DBZ plus dexamethasone (Fig. 5c) , suggesting that Notch signaling could participate in the negative control of Klf4 expression in the gut. Consistent with this hypothesis, luciferase reporter assays indicated that activation of NOTCH signaling by ICN1 downregulates the activity of the KLF4 promoter in the AGS gastric adenocarcinoma cell line ( Fig. 5d ) and HCT116 colon adenocarcinoma cells ( Supplementary Fig. 16 online) . Notably, Hes1knockout mice have an increased number of goblet cells in the gut 40 , suggesting that Hes1 can work as a transcriptional repressor controlling Klf4 expression downstream of Notch signaling. Luciferase reporter assays confirmed this hypothesis, showing that HES1 expression downregulates the activity of the KLF4 promoter ( Fig. 5d,e ). Furthermore, ChIP showed binding of HES1 protein to the KLF4 promoter ( Fig. 5f) , whereas shRNA knockdown of HES1 induced upregulation of KLF4 transcripts (Fig. 5g) , and HES1 overexpression downregulated the expression of KLF4 transcripts (Fig. 5h) . Overall, these experiments demonstrate that KLF4 is a direct transcriptional target of HES1 downstream of NOTCH signaling in the gut and support a mechanistic role for Klf4 upregulation downstream of NOTCH inhibition in GSI-induced gut toxicity.
Ccnd2 upregulation by dexamethasone reverses GSI gut toxicity To elucidate the mechanism responsible for the reversal of GSI-induced toxicity in mice treated with glucocorticoids, we performed gene expression profiling with oligonucleotide microarrays of the small intestine of mice treated with vehicle (DMSO), dexamethasone, DBZ or the combination of DBZ plus dexamethasone. This analysis identified Ccnd2, a key regulator of cell cycle progression, among the genes upregulated by dexamethasone ( Fig. 6a) . Quantitative RT-PCR analysis confirmed that Ccnd2 expression in the gut was upregulated in mice treated with dexamethasone compared to controls (P o 0.001; Fig. 6b ). Notably, growth arrest and cell differentiation are temporally and functionally linked events in the intestinal epithelium 41 , and expression of Ccnd2 in AGS cells induced a marked decrease in KLF4 transcript levels ( Fig. 6c ), suggesting that upregulation of Ccnd2 expression by dexamethasone may mediate, at least in part, the protective effects of glucocorticoids against GSI-induced goblet cell metaplasia. To address this question, we analyzed the effects of dexamethasone, DBZ or the combination of DBZ plus dexamethasone in Ccnd2-knockout mice 42 . As observed in wild-type mice, dexamethasone treatment induced accumulation of Paneth cells at the bottom of the intestinal crypt in Ccnd2-knockout mice (Fig. 6d,e ). However, this increase in cell differentiation toward the Paneth cell lineage was associated with decreased cell numbers and a reduction of Ki67positive cells per crypt, which was in contrast with the moderate cell expansion induced by glucocorticoid treatment in the intestine of wildtype mice (Fig. 6d,e ). Moreover, when treated with DBZ plus dexamethasone, Ccnd2-knockout mice developed GSI-induced goblet cell metaplasia (Fig. 6f ) associated with increased Klf4 expression in the gut (Fig. 6g) . Histological analysis of the spleen showed no differences between wild-type and Ccnd2-deficient mice and served as positive control for the activity of DBZ and dexamethasone in this experiment (Fig. 6f) . Overall, these results highlight the functional relevance of Ccnd2 upregulation induced by dexamethasone treatment for the protection from GSI-induced toxicity in the gut (Fig. 6h , Supplementary Results and Supplementary Discussion).
DISCUSSION
Despite the strong rationale for inhibiting NOTCH1 signaling in the treatment of individuals with T-ALL harboring activating mutations in the NOTCH1 gene, progress in clinical testing of GSIs has been hindered by the lack of effective antileukemic cytotoxicity and the development of severe gastrointestinal toxicity 5, [8] [9] [10] [11] 20 . On the basis of the hypothesis that the combination of NOTCH1 inhibition with chemotherapy might provide an improved therapeutic window, we tested the activity of a GSI with conventional antileukemic agents. These studies showed that inhibition of NOTCH1 signaling can effectively abrogate glucocorticoid resistance in T-ALL primary human samples and cell lines. Additional pharmacologic interactions affecting glucocorticoid resistance in T-ALL have been described before. Most notably, inhibition of mammalian target of rapamycin (mTOR) signaling with rapamycin can reverse glucocorticoid resistance in leukemic lymphoblasts by inducing post-transcriptional downregulation of myeloid cell leukemia sequence-1, (ref. 43); however, we did not detect changes in the protein expression of this antiapoptotic factor in cells treated with Compound E plus dexamethasone (data not shown). Similarly, we did not detect changes in the differentiation arrest of T-ALL cells that could be linked to differential glucocorticoid sensitivity or transcriptional changes in the SRG3 gene (encoding a chromatin-remodeling factor, data not shown), two mechanisms proposed to reduce the sensitivity to glucocorticoid-induced apoptosis downstream of NOTCH1 activation in mouse primary thymocytes 14, [44] [45] [46] . Analysis of therapeutic efficacy in leukemia-bearing mice treated with a highly active GSI plus dexamethasone in vivo showed increased antileukemic effects but also a surprising decrease in GSI-induced gut toxicity. Molecular analysis of the mechanisms mediating the goblet cell metaplasia induced by inhibition of NOTCH signaling in the gut identified KLF4, a transcription factor responsible for goblet cell differentiation, as a potential mediator of GSI-induced intestinal toxicity. Thus, a possible explanation to account for the protective effects of dexamethasone against GSI-induced gut toxicity in vivo would be an inhibitory effect of glucocorticoids on the expression of Klf4. However, luciferase reporter assays did not detect regulation of KLF4 promoter activity by dexamethasone ( Supplementary Fig. 17  online) . These negative results suggest that an indirect effect accounts for the downregulation of Klf4 expression in mice treated with a GSI plus dexamethasone.
Detailed characterization of the effects of dexamethasone in the intestinal epithelium showed that glucocorticoids induce a moderate increase in proliferation associated with Ccnd2 upregulation and promote differentiation of intestinal progenitors into Paneth cells. Given that Klf4 is a negative regulator of the cell cycle, we explored the possibility that dexamethasone-induced Ccnd2 upregulation could antagonize the expression of Klf4 in the gut. Consistent with this hypothesis, in vitro studies in AGS cells showed that forced expression of Ccnd2 resulted in decreased levels of KLF4 transcripts. Moreover, in vivo analysis of Ccnd2-deficient mice treated with a GSI plus dexamethasone showed accumulation of goblet cells and elevated Klf4 expression, similar to that observed in mice treated with a GSI alone. These results suggest that dexamethasone-induced Ccnd2 upregulation is strictly required for the enteroprotective effects of glucocorticoids against GSI-induced gut toxicity.
Overall, our results support that combination therapies with GSIs plus glucocorticoids may be effective against glucocorticoid-resistant T-ALL, identify glucocorticoids as key regulators of cell fate determination and tissue homeostasis in the gut and suggest that concurrent treatment with glucocorticoids may facilitate the clinical development of GSIs by protecting individuals from the intestinal toxicity typically associated with inhibition of NOTCH signaling in the gut. Cell viability studies and gene and protein expression analysis. We performed cell viability assays, retroviral and lentiviral transduction, microarray analysis, quantitative RT-PCR, luciferase reporter assays, chromatin immunoprecipitation, western blot and immunohistochemistry assays following standard procedures, which are detailed in the Supplementary Methods online.
Mice and mouse procedures. We kept all mice in specific pathogen-free animal facilities at Memorial-Sloan Kettering Cancer Center, New York University Medical Center and Columbia University Medical Center. We performed all mouse procedures in accordance with the guidelines of the Memorial-Sloan Kettering Cancer Center, New York University Medical Center and Columbia University Medical Center Institutional Animal Care and Use Committees. We performed xenograft experiments with 6-8-week-old NOD-SCID female mice (Taconic Farms) as recipients. We carried out toxicity experiments in 6-week-old C57/BL6 female mice (Jackson Laboratory) and Ccnd2-knockout mice. Ccnd2-knockout mice have been previously described 42 .
To analyze the effects of dexamethasone in GSI-induced toxicity, we treated mice with vehicle (DMSO), dexamethasone (15 mg kg -1 ), DBZ (10 mmol kg -1 ) and dexamethasone (15 mg kg -1 ) plus DBZ (10 mmol kg -1 ) daily by intraperitoneal injection for 5 and 10 d. At the end of the treatment, we killed the mice and collected and processed tissues and organs for histological and immunohistochemical analysis.
We generated mice for inducible deletion of Rbpj by breeding Rbpj flox/flox conditional knockout mice 47 to the Cre-Tam mouse line, which expresses a tamoxifen-inducible Cre from the ubiquitous Rosa26 locus 37 . We treated Rbpj flox/flox Cre-Tam mice with tamoxifen (1 mg) by oral gavage daily for 3 d to induce Rbpj deletion. To analyze the effect of dexamethasone treatment in the induction of goblet cell metaplasia induced by Notch inactivation via Rbpj deletion, we injected Rbpj flox/flox Cre-Tam tamoxifen-treated mice with dexamethasone (15 mg kg -1 ) (n ¼ 3) or vehicle only (n ¼ 3) via intraperitoneal injection for 10 d, starting on the first day of tamoxifen treatment. We evaluated the effects of tamoxifen and dexamethasone treatment in the gut through histological and immunohistochemical analysis.
We generated luminiscent CUTLL1 cells by infecting the CUTLL1 cell line with FUW-luc lentiviruses followed by selecting with neomycin (1 mg ml -1 ); we verified luciferase expression in vitro with the Dual-Luciferase Reporter Assay kit (Promega). For subcutaneous xenograft experiments, we injected 2.5 Â 10 6 T-ALL cells embedded in Matrigel (BD Biosciences) in the flank. After 1 week, we segregated the mice into treatment groups (six mice per group) and treated them daily with vehicle (DMSO), dexamethasone (15 mg kg -1 ), DBZ (10 mmol kg -1 ) or dexamethasone (15 mg kg -1 ) plus DBZ (10 mmol kg -1 ) by intraperitoneal injection. For imaging studies, we anesthetized the mice by isoflurane inhalation and injected them with D-luciferin at 50 mg kg -1 (Xenogen) intraperitoneally. We imaged photonic emission with the In Vivo Imaging System (IVIS, Xenogen) with a collection time of 1 min. We quantified tumor bioluminescence by integrating the photonic flux (photons per second) through a region encircling each tumor, as determined by the LIVING IMAGES software package (Xenogen).
For intravenous xenograft transplantation, we irradiated recipient mice with a total X-ray dose of 300 cGy. We injected two million CUTLL1 cells expressing luciferase via the tail vein. After a 3-week window for tumor engraftment, we segregated mice with homogeneous tumor burdens into treatment groups (eight mice per group) and treated them daily with vehicle (DMSO), dexamethasone (15 mg kg -1 ), DBZ (10 mmol kg -1 ) or dexamethasone (15 mg kg -1 ) plus DBZ (10 mmol kg -1 ) by intraperitoneal injection for 14 d. We evaluated disease progression and therapy response weekly with bioimaging as described above by integrating the photonic flux (photons per second) through a region around each mouse. We followed up on the mice for up to 10 weeks. At the end of the observation period, we analyzed single-cell suspensions from the spleens of surviving mice for the presence of leukemic cells by flow cytometry after staining with FITC-labeled human antibody to CD45 (BD Biosciences).
Statistical analyses. We performed statistical analysis by Student's t-test. Survival in mouse experiments was represented with Kaplan-Meier curves, and significance was estimated with the log-rank test. Values were considered statistically significant at P o 0.05.
Accession codes. Microarray data are available at Gene Expression Omnibus (accession numbers GSE7067 and GSE11184).
Note: Supplementary information is available on the Nature Medicine website.
